Market news

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees. Included in these awards were grants of employment inducement awards to Jason Knoblauch, the Company’s recently appointed Chief Financial Officer, as an inducement material to

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026Format: Fireside Chat & 1x1 and Group MeetingsTime: 2:00 -2:30 PM EDTWebcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcar

Check out the companies making headlines this week:

Check out the companies making headlines yesterday:

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 3% in the afternoon session after the company agreed to acquire the Early Phase Services division of Worldwide Clinical Trials.

Fortrea (FTRE) has agreed to acquire the Early Phase Services division of Worldwide Clinical Trials

Fortrea has been on fire lately. In the past six months alone, the company’s stock price has rocketed 77%, reaching $18.31 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Fortrea (NASDAQ:FTRE) and the best and worst performers in the drug development inputs & services industry.

Drug Development Inputs & Services Stocks Q2 In Review: Fortrea (NASDAQ:FTRE) Vs Peers

Investment management company Curreen Capital released its second-quarter 2026 Investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 22.26% compared to 15.20% for the S&P 500 Index. The performance was driven by active special case investments, including buying a tender offer, a merger-spinoff, and investments in […]

Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.

Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Fortrea (NASDAQ:FTRE) reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving com

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2 millionBook-to-bill ratio of 1.06x, resulting in 1.12x book-to-bill for the trailing 12 monthsGAAP net loss of $(13.2) million, or $(0.14) per diluted shareAdjusted EBITDA of $58.7 millionAdjusted net income of $22.7 million, or $0.23 per diluted shareCash provided by operations of $28.9 million and f

Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 4.5% year on year to $678.2 million. The company’s full-year revenue guidance of $2.66 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $0.23 per share was 27.2% above analysts’ consensus estimates.

Fortrea Holdings Inc (FTRE) reports improved revenue guidance and sustained commercial momentum, despite facing revenue decline and leadership changes.

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results this Wednesday morning. Here’s what to look for.

Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.

DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive

Fortrea Holdings (FTRE) has drawn fresh attention after recent trading left the stock at $17.76, with short term moves over the past week and month adding context to its longer term performance profile. See our latest analysis for Fortrea Holdings. Over the past year, Fortrea Holdings has seen a sharp shift in sentiment, with a 1 year total shareholder return of 247.55% and a 90 day share price return of 93.46%. However, the 3 year total shareholder return is down 45.39%, suggesting that...

Fortrea Holdings has delivered a 247.6% return over the past year, yet the stock still screens as undervalued on broader valuation checks. This raises a clear question about how much of that rerating is already reflected in the current US$17.76 share price. Over the past 1 year, Fortrea Holdings has returned 247.6%, which puts the recent rally front and center for anyone thinking about the stock today. Future revenue and cash flow expectations can support the current valuation, while any...

Detailed price information for Hamilton Insurance Group Ltd Cl B (HG-N) from The Globe and Mail including charting and trades.